Medtronic PLC Form 4 insider transactions

Denise L. Blomquist, Chief Accounting Officer of Medtronic plc, reported multiple transactions in common stock on July 31, 2026.

Matthew R. Walter, SVP, Chief HR Officer of Medtronic plc, reported multiple transactions in common stock on July 31, 2026.

Kweli Thompson, EVP & President, Neuroscience of Medtronic plc, reported multiple transactions in common stock on July 31, 2026.

Michelle Quinn, EVP, GC and Secretary of Medtronic plc, reported multiple transactions in common stock on August 3, 2026.

Thierry Pieton, EVP & Chief Financial Officer of Medtronic plc, reported multiple transactions in common stock on August 3, 2026.

Michael Marinaro, EVP, Pres MedSurg and Americas of Medtronic plc, reported multiple transactions in common stock on July 31, 2026.

Harry Skip Kiil, EVP & President Cardiovascular of Medtronic plc, reported multiple transactions in common stock on July 31, 2026.

Geoffrey Martha, Chairman and CEO and a Director of Medtronic plc, reported multiple transactions in common stock on July 31, 2026.

Michelle Quinn, EVP, GC and Secretary of Medtronic plc, reported a transaction in 2,069 shares of common stock on July 28, 2026.

Medtronic plc reports a transaction where SVP, Chief HR Officer Walter Matthew R. sold 3,102 ordinary shares.

Medtronic plc executive Harry Skip Kiil reported the sale of company shares on June 8, 2026, totaling 4,189 ordinary shares.

EVP & President of Cardiovascular Harry Skip Kiil disposed of 6,817 Medtronic shares to cover tax obligations.

Medtronic Chairman and CEO Martha Geoffrey reported the withholding of 41,936 shares to cover tax obligations related to vested restricted stock units.

Medtronic EVP Michael Marinaro disposed of 7,471 shares to satisfy tax obligations related to vested restricted stock units.

SVP and Chief HR Officer Matthew R. Walter disposed of 2,840 shares of Medtronic plc to satisfy tax withholding obligations.

Medtronic Chief Accounting Officer Denise L. Blomquist reported the withholding of 237 ordinary shares to cover tax obligations related to vested restricted stock units.

Medtronic SVP and Chief HR Officer Matthew R. Walter acquired 9,149 ordinary shares following the settlement of performance-vesting units.

Medtronic EVP Brett A. Wall acquired 26,907 ordinary shares following the settlement of performance-vesting share units.

Medtronic Chairman and CEO Martha Geoffrey acquired 94,963 ordinary shares following the settlement of performance-vesting share units.

Medtronic EVP Michael Marinaro acquired 18,994 ordinary shares following the settlement of performance-vesting units.

Medtronic EVP Harry Skip Kiil acquired 15,195 ordinary shares following the settlement of performance-vesting share units.

Medtronic Chief Accounting Officer Denise Blomquist acquired 1,712 ordinary shares following the settlement of performance-vesting share units.

Medtronic plc reports a Form 4 filing detailing changes in beneficial ownership for SVP, Chief HR Officer Walter Matthew R.

Denise L. Blomquist, Chief Accounting Officer at Medtronic plc, reported transactions involving ordinary shares and restricted stock units.

Medtronic plc director Kendall J. Powell reported transactions involving ordinary shares, including an award of restricted stock units and shares withheld for tax payments.

Medtronic plc reports a Form 4 filing detailing stock transactions by Director Kevin E. Lofton, including restricted stock unit awards and tax withholdings.

Medtronic plc reports a transaction where Director William R. Jellison acquired 1,444 ordinary shares.

Medtronic plc reports on insider transactions, with Director Scott C. Donnelly acquiring restricted stock units and disposing of shares for tax payments.

Medtronic plc director Craig Arnold reported transactions involving ordinary shares, including an award of restricted stock units and shares withheld for tax payments.

Medtronic's EVP & CFO, Thierry Pieton, reported a disposal of 2,976 ordinary shares for tax purposes, while also increasing beneficial ownership through dividend reinvestment.